Screening for depression in adult acne vulgaris patients: tools for the dermatologist
Article first published online: 25 NOV 2003
Journal of Cosmetic Dermatology
Volume 1, Issue 4, pages 202–207, December 2002
How to Cite
Henkel, V., Mœhrenschlager, M., Hegerl, U., Mœller, H.-J., Ring, J. and Worret, W.-I. (2002), Screening for depression in adult acne vulgaris patients: tools for the dermatologist. Journal of Cosmetic Dermatology, 1: 202–207. doi: 10.1111/j.1473-2165.2002.00057.x
- Issue published online: 25 NOV 2003
- Article first published online: 25 NOV 2003
- Accepted for publication 31 January 2003
- acne vulgaris;
Summary Background Adult dermatological out patients have a 40% prevalence of psychiatric co-morbidity. If psychiatric co-morbidity is unrecognized, undetected and untreated, the consequences may be fatal. Acne is the most common skin disorder of the second and third decades of life. Acne and its treatments may cause depression.
Aims To identify a screening tool to identify depression in adult acne patients.
Methods The literature was reviewed to identify validated screening instruments for depressive disorders. Questionnaires studied included the Hospital Anxiety and Depression Scale (HAD), the Brief Patient Health Questionnaire (B-PHQ), the General Health Questionnaire-12 item version (GHQ-12), and the World Health Organization-5 Well Being Index (WHO-5).
Results WHO-5 performed best in terms of sensitivity (0.93 for a cut-off score of 13) as well as taking least time to complete (2–5 min) and evaluate (0.5–2 min).
Conclusions WHO-5 can be recommended as part of a two-step screening process for depression in acne patients. Step 1 is the WHO-5. In the case of a positive score, step 2 is a detailed psychosocial assessment.